Pre-treatment Interferon-Gamma Inducible Protein 10 (IP-10) is Associated with Recurrent Drug-Resistant Tuberculosis
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Article Sidebar
Lestiono, Oki Nugraha Putra (2026). Pre-treatment Interferon-Gamma Inducible Protein 10 (IP-10) is Associated with Recurrent Drug-Resistant Tuberculosis. Journal of Pharmaceutical and Sciences, JPS Volume 9 Nomor 4 (2026). https://doi.org/10.36490/journal-jps.com.v9i4.1268
Main Article Content
Abstract
Background: IP-10, a chemokine, is found in high levels in drug-resistant tuberculosis (DR-TB) patients. This study analyzed the pre-treatment IP-10 level and its association among recurrent DR-TB patients. Method: A case-control study was conducted among DR-TB patients, newly diagnosed as the control group and the recurrent as the case group. IP-10 level was measured using the sandwich ELISA method. We used Mann-Whitney to analyze the differences in IP-10 levels between the two groups. Results: 72 DR-TB patients enrolled in this study and 45 (62.5%) were recurrent cases. The median (IQR) of IP-10 was higher in recurrent than in newly diagnosed DR-TB, 1876.4 (625.2-8313) vs 1304 (590.4-2001) pg/ml, respectively, with a P-value of 0.001. Among recurrent DR-TB, those with lung cavities had higher IP-10 levels than those without, P-value = 0.001. According to the ROC curve, the optimal cut-off value of IP-10 was 1555.6 pg/mL, with a sensitivity and specificity of 66.7% in predicting recurrent cases. The pre-treatment of IP-10 level ≥ 1555.6 pg/ml was significantly associated with recurrent DR-TB (OR = 3.625; 95% CI: 1.325-9.917), and IP-10 level ≥ 2012.4 pg/ml was significantly associated with lung cavity among recurrent DR-TB patients (OR = 7.429; 95% CI: 1.939-28.466). IP-10 level correlates with sputum smear grading (P-value=0.010; Spearman rho=0.506) among recurrent DR-TB patients. Conclusion: IP-10 level was significantly high among recurrent DR-TB patients and those with lung cavities. An IP-10 level ≥ 1555.6 pg/ml is associated with recurrent DR-TB in this case-control study. IP-10 level ≥ 2012.4 pg/ml is significantly associated with lung cavities among recurrent DR-TB patients.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
[1]. World Health Organization. Global tuberculosis report 2024. World Health Organization; 2024.
[2]. Sinulingga HE, Sinaga BYM, Siagian P, Ashar T. Profile and risk factors of pre-XDR-TB and XDR-TB patients in a national reference hospital for Sumatra region of Indonesia. Narra J. 2023;3:7-12
[3]. Wotale TW, Lelisho ME, Negasa BW, Tareke SA, Gobena WE, Amesa EG. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient’s record data from 2016 to 2021: retrospective study. Sci Rep. 2024;14:23912
[4]. Youn HM, Shin MK, Jeong D, Kim HJ, Choi H, Kang YA. Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study. PLoS One. 2022;17:e0268290
[5]. Shanmuganathan G, Orujyan D, Narinyan W, Poladian N, Dhama S, Parthasarathy A, et al. Role of Interferons in Mycobacterium tuberculosis Infection. Clin Pract. 2022;12:788–96.
[6]. Le Y, Cao W, Zhou L, Fan X, Liu Q, Liu F, et al. Infection of Mycobacterium tuberculosis Promotes Both M1/M2 Polarization and MMP Production in Cigarette Smoke-Exposed Macrophages. Front Immunol. 2020;11:1902
[7]. Efriyani YI, Parwati I, Tristina N, Tjandrawati A. IP-10 as a Non Sputum Biomarker in TB Treatment Monitoring. Majalah Kedokteran Bandung. 2021;53:17-21
[8]. Alisjahbana B, Sulastri N, Livia R, Apriani L, Verrall AJ, Sahiratmadja E. Neutrophils and lymphocytes in relation to MMP-8 and MMP-9 levels in pulmonary tuberculosis and HIV co-infection. J Clin Tuberc Other Mycobact Dis. 2022;27:100308
[9]. Ali ZA, Mankhi AA, Ad’hiah AH. Significance of the chemokine CXCL10 and human beta-defensin-3 as biomarkers of pulmonary tuberculosis. Tuberculosis. 2021;128:102078
[10]. Strzelak A, Komorowska-Piotrowska A, Borowa A, Krasińska M, Feleszko W, Kulus M. IP-10 for the Diagnosis and Treatment Monitoring of Tuberculosis in Children. Diagnostics. 2024 ;14:177
[11]. Muchsin S, Priyanto H, Zulfikar T, Kurniawan FD. The Difference in Serum Levels of IP-10 in Patients with Pulmonary Tuberculosis with A Positive AFB and AFB Conversion. Jurnal Respirologi Indonesia. 2022 ;42:18-24
[12]. Setyawan MF, Mertaniasih NM, Soedarsono S, Nuha Z, Maladan Y, Matsumoto S. Mycobacterium tuberculosis-AtpE gene profile of bedaquiline-Treated pulmonary tuberculosis patients at the referral hospital Dr. Soetomo, Indonesia. Int J Mycobacteriol. 2023;12:122–8.
[13]. Khan AS, Phelan JE, Khan MT, Ali S, Qasim M, Napier G, et al. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. Sci Rep. 2021;11:14194
[14]. Putra ON, Yulistiani Y, Soedarsono S, Subay S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review. Int J Mycobacteriol. 2023;12:1-9
[15]. Bade AB, Mega TA, Negera GZ. Malnutrition is associated with delayed sputum culture conversion among patients treated for mdr-tb. Infect Drug Resist. 2021;14:1659–67.
[16]. Li S, Liang Y, Hu X. Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus. BMC Infect Dis. 2022;22:835
[17]. Araia ZZ, Mesfin AB, Mebrahtu AH, Tewelde AG, Osman R, Tuumzghi HA. Diabetes mellitus and its associated factors in tuberculosis patients in Maekel region, Eritrea: Analytical cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:515–23.
[18]. Kassa GM, Merid MW, Muluneh AG, Fentie DT. Sputum smear grading and associated factors among bacteriologically confirmed pulmonary drug-resistant tuberculosis patients in Ethiopia. BMC Infect Dis. 2021;21:238
[19]. Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA, Jain SK, Bishai WR. Cavitary tuberculosis: the gateway of disease transmission. Lancet Infect Dis. 2020;20:e117–28.
[20]. Pradana RF, Nawawi YS, Satoto B. Chest X-Ray Evaluation of Cavitary Lesions among Pulmonary MDR-TB Patients. eJKI. 2018;6:1–4.
[21]. Chen L, Zhang J, Zhang H. A large pulmonary cavity replaced by a tuberculosis granuloma and healed during treatment of a patient with tuberculosis. J Infect Dev Ctries. 2018;12:60–2.
[22]. Sampath P, Rajamanickam A, Thiruvengadam K, Natarajan AP, Hissar S, Dhanapal M, et al. Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis. Sci Rep. 2023;13:7404
[23]. Mutavhatsindi H, Manyelo CM, Snyders CI, Rensburg IV, Kidd M, Stanley K., et al. Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis. J Infect. 2024;89:106173
[24]. Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, et al. International Journal of Infectious Diseases First description of agonist and antagonist IP-10 in urine of patients with active TB. Int J Infect Dis. 2019;78:15–21
[25]. Aravindhan V, Kevinkumar V, Dhamodharan U, Viswanathan V. Serum levels of chemokines IP-10, IL-8 and SDF-1 serve as good biomarkers for diabetes-tuberculosis nexus. J Diabetes Complications. 2018;32:857–62.
[26]. Mvo S, Bokop C, Longo-Mbenza B, Vasaikar SD, Apalata T. Prolongation of Acid-Fast Bacilli Sputum Smear Positivity in Patients with Multidrug-Resistant Pulmonary Tuberculosis. Pathogens. 2023;12:1133
[27]. Rahmasena N, Marhana IA, Suwandi MYS, Kusmiati T, Jearanaiwitayakul T. Factors Associated with Acid Fast Bacilli and Sputum Culture Conversion in Patients with Multidrug-Resistant Tuberculosis in Surabaya. Biomolecular and Health Science Journal. 2021;4:107.